Current Technology: Devices Available for Destination Therapy - 06/11/11
Doi : 10.1016/j.ccl.2011.08.005
Hiroo Takayama, MD, Jonathan A. Yang, MD, Yoshifumi Naka, MD, PhD ⁎ 
Department of Surgery, Columbia University Medical Center, Milstein Hospital Building, 7-435, 177 Fort Washington Avenue, New York, NY 10032, USA
Corresponding author.Résumé |
Left ventricular assist device therapy as a destination therapy for end-stage heart failure has made a large leap with continuous flow devices. Continuous flow does not seem to have a detrimental effect on end-organ function, at least in the midterm. Various expected and unexpected complications have been reported associated with this technology. More experience and research are warranted.
Le texte complet de cet article est disponible en PDF.Keywords : Destination therapy, HeartMate XVE, HeartMate II, HeartWare
Plan
| Yoshifumi Naka receives consultant fee from Thoratec and DuraHeart. The other authors have nothing to disclose. |
© 2011
Publié par Elsevier Masson SAS.
Vol 29 - N° 4
P. 499-504 - novembre 2011 Retour au numéro
Article précédent
- Editorial Comment on “Natural History of End-Stage LV Dysfunction: Has it Improved from the Classic Franciosa and Cohn Graph?”
- John A. Elefteriades
- Editorial Comments on “Current Technology—Devices Available for ‘Destination’ Therapy”
- John A. Elefteriades
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?